Strategic Science & Technologies (SST) is a Cambridge, MA-based clinical stage biotechnology company with an innovative topical drug delivery technology. With a focus on formulating known active pharmaceutical ingredients, SST aims to become the first FDA approved product for the treatment of Female Sexual Arousal Disorder (FSAD). The company's patented delivery technology allows for targeted local delivery of active pharmaceutical ingredients at therapeutic levels, providing effective and efficient treatment options.

SST has advanced three programs into clinical trials, demonstrating their commitment to bringing innovative solutions to market. In recent news, SST has announced initiation of a Content Validity Study and enrollment in a Thermography Feasibility Study, which further showcases their dedication to research and development. With their pipeline of promising products and collaborations, Strategic Science & Technologies is at the forefront of biotechnology advancements in treating FSAD.

Contact SST today to learn more about their groundbreaking solutions